Rain Oncology Inc. Operating Income
Rain Oncology Inc. reported Operating Income of -$8.08 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2023-11-09
- Rain Oncology Inc. operating income (loss) for the quarter ending 2023-09-30 was -$8.08M.
- Rain Oncology Inc. operating income (loss) for the quarter ending 2023-06-30 was -$23.23M.
- Rain Oncology Inc. operating income (loss) for the quarter ending 2023-03-31 was -$21.74M.
- Rain Oncology Inc. operating income (loss) for the quarter ending 2022-12-31 was -$23.56M.
- Rain Oncology Inc. operating income (loss) for fiscal 2022 was -$77.14M.
- Rain Oncology Inc. operating income (loss) for fiscal 2021 was -$51.51M.
- Rain Oncology Inc. operating income (loss) for fiscal 2020 was -$18.96M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$8.08M 10-Q · filed 2023-11-09 | -$31.31M derived: sum of 2 quarters · filed 2023-11-09 | -$53.05M 10-Q · filed 2023-11-09 | -$76.61M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | -$23.23M 10-Q · filed 2023-08-10 | -$44.97M 10-Q · filed 2023-08-10 | -$68.53M derived: sum of 3 quarters · filed 2023-08-10 | -$86.94M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-03-31 | -$21.74M 10-Q · filed 2023-05-11 | -$45.30M derived: sum of 2 quarters · filed 2023-05-11 | -$63.71M derived: sum of 3 quarters · filed 2023-11-09 | -$81.43M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | -$23.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$41.97M derived: sum of 2 quarters · filed 2023-11-09 | -$59.69M derived: sum of 3 quarters · filed 2023-11-09 | -$77.14M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$18.41M 10-Q · filed 2023-11-09 | -$36.13M derived: sum of 2 quarters · filed 2023-11-09 | -$53.58M 10-Q · filed 2023-11-09 | -$71.66M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$17.72M 10-Q · filed 2023-08-10 | -$35.17M 10-Q · filed 2023-08-10 | -$53.24M derived: sum of 3 quarters · filed 2023-08-10 | -$71.68M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$17.45M 10-Q · filed 2023-05-11 | -$35.53M derived: sum of 2 quarters · filed 2023-05-11 | -$53.97M derived: sum of 3 quarters · filed 2023-05-11 | -$62.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$18.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$36.52M derived: sum of 2 quarters · filed 2023-03-09 | -$44.70M derived: sum of 3 quarters · filed 2023-03-09 | -$51.51M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$18.44M 10-Q · filed 2022-11-10 | -$26.63M derived: sum of 2 quarters · filed 2022-11-10 | -$33.44M 10-Q · filed 2022-11-10 | -$38.89M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$8.19M 10-Q · filed 2022-08-04 | -$15.00M 10-Q · filed 2022-08-04 | -$20.45M derived: sum of 3 quarters · filed 2022-08-04 | -$28.93M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$6.81M 10-Q · filed 2022-05-04 | -$12.26M derived: sum of 2 quarters · filed 2022-05-04 | -$20.74M derived: sum of 3 quarters · filed 2022-05-04 | -$23.34M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$13.94M derived: sum of 2 quarters · filed 2022-03-03 | -$16.53M derived: sum of 3 quarters · filed 2022-03-03 | -$18.96M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$8.48M 10-Q · filed 2021-11-10 | -$11.08M derived: sum of 2 quarters · filed 2021-11-10 | -$13.51M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.59M 10-Q · filed 2021-08-10 | -$5.02M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$2.43M 10-Q · filed 2021-05-25 |